Articles related to DRUG DISCOVERIES

A phase 3 trial demonstrates that aficamten improves oxygen utilization during exercise for obstructive HCM patients, indicating its potential to enhance daily functionality and quality of life.

In a landmark effort, seven molecules targeting the genetic roots of familial Parkinson’s disease were identified, showcasing the power of AI and open science in advancing treatment options. This collaborative achievement offers new avenues for understanding and potentially treating this challenging neurological disorder.

Discover the latest advancements in ADHD therapies that promise greater efficacy and fewer side effects—options that can revolutionize personalized treatment plans.

The recent phase 3 trial of vorasidenib in patients with grade 2 IDH-mutant glioma has demonstrated significant improvements in progression-free survival and time to next intervention. Explore the detailed findings to understand how this oral inhibitor could become a vital part of the treatment regimen for this challenging condition.

The landscape of small cell lung cancer treatment is undergoing significant transformation with the advent of immune checkpoint inhibitors. This shift not only provides new therapeutic options but emphasizes the importance of a comprehensive team approach, including early detection strategies, and holds the promise for enhanced patient prognosis.

The field of gastric and esophageal cancer treatment is witnessing remarkable advancements through targeted therapies and immunotherapies. Explore the latest clinical trials and discoveries that are redefining the standard of care for these traditionally difficult-to-treat cancers.